Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy—Real-World Clinical Impressions and Comparative Review of the Literature

Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy—Real-World Clinical Impressions and Comparative Review of the Literature

Background: The introduction of checkpoint inhibitors is a long-awaited new option for a urothelial cancer with a poor prognosis. Apart from clinical studies, the data on real world experience is scarce.Methods: Patients for monotherapy with either Atezolizumab, Nivolumab or Pembrolizumab after chem...

Full description

Bibliographic Details
Main Authors: Christian Fuhrmann, Julian P. Struck, Philipp Ivanyi, Mario W. Kramer, Marie C. Hupe, Bennet Hensen, Alexander Fürschke, Inga Peters, Axel S. Merseburger, Markus A. Kuczyk, Christoph-A. J. von Klot
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Oncology
Subjects:
metastatic urothelial carcinoma
checkpoint inhibition
immunotherapy
atezolizumab
pembrolizumab
nivolumab
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00808/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00808/full

Similar Items